Moderna stock gained 0.57 percent as Nasdaq-100 entry nears
Published on 10/04/2026 at 17:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. (ISIN US60770K1079) stock closed at USD 190.01 on Nasdaq on October 2, 2026, gaining 0.57 percent on the session. Nasdaq announced on October 1 that Moderna will enter the Nasdaq-100 before market open on October 9, a move that places the biotechnology company in a major benchmark tracked by more than 200 investment products, according to GlobeNewswire.
Index entry sets the near term
The Nasdaq-100 change replaces Warner Bros. Discovery and takes effect before the October 9 opening bell. For Moderna, the timing matters because index-tracking funds must adjust their holdings around the change, while the stock remains USD 18.89 below its 52-week high of USD 208.90.
Moderna's October 2 session reached USD 193.72 at the high and USD 183.28 at the low, with an opening price of USD 190.26. The closing gain followed a 1.89 percent decline on October 1, leaving the shares close to the upper end of the current USD 22.28 to USD 208.90 52-week range.
Revenue growth meets a deep loss
Moderna reported second-quarter 2026 revenue of USD 145 million, up 2.1 percent from USD 142 million in the same quarter of 2025, while its GAAP net loss narrowed to USD 782 million from USD 825 million, according to RTTNews.
The quarterly GAAP loss per share was USD 1.97, compared with USD 2.13 a year earlier. Moderna also reiterated its 2026 revenue-growth outlook of up to 10 percent in its second-quarter update, while the company continues to invest in vaccines and its oncology pipeline.
Analysts remain far below the market
MarketBeat shows a Hold consensus from 25 analysts, comprising 7 Buy, 13 Hold and 5 Sell ratings. Its average twelve-month price target is USD 77.83, with a high target of USD 180.00 and a low target of USD 18.00, according to MarketBeat.
Citi moved Moderna from Neutral to Sell on September 30, 2026, while raising its price target from USD 60.00 to USD 80.00, TheStreet reported. That view contrasts with the index inclusion and the companys recent oncology-driven rerating, leaving upcoming clinical data as an important test of the current valuation.
Upcoming events define the next test
Moderna will host an investor event on October 24, 2026, linked to data presented at the ESMO Congress, according to its company media room. TheStreet also identifies November 12, 2026, as the date for Moderna's Analyst Day.
Moderna stock closed at USD 190.01
Moderna stock closed at USD 190.01 on Nasdaq on October 2, 2026, with a market capitalization of USD 75.4 billion. The combination of Nasdaq-100 inclusion, a 2.1 percent year-over-year revenue increase and a USD 782 million quarterly GAAP loss gives investors three distinct measures for judging the shares.
Moderna stock at a glance
- Company: Moderna, Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Trading venue: Nasdaq
- Price (as of October 2, 2026): Closing price USD 190.01
- Market capitalization: USD 75.4 billion (as of October 2, 2026)
- 52-week range: USD 22.28-208.90 (as of October 2, 2026)
- Sector / Industry: Biotechnology
- Index membership: Nasdaq-100 effective October 9, 2026
Upcoming dates for Moderna stock
- October 24, 2026: Investor event via webcast
- November 12, 2026: Analyst Day
